1. Home
  2. EXPO vs GRFS Comparison

EXPO vs GRFS Comparison

Compare EXPO & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXPO
  • GRFS
  • Stock Information
  • Founded
  • EXPO 1967
  • GRFS 1940
  • Country
  • EXPO United States
  • GRFS Spain
  • Employees
  • EXPO 1320
  • GRFS N/A
  • Industry
  • EXPO Professional Services
  • GRFS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EXPO Consumer Discretionary
  • GRFS Health Care
  • Exchange
  • EXPO Nasdaq
  • GRFS Nasdaq
  • Market Cap
  • EXPO 4.6B
  • GRFS 5.5B
  • IPO Year
  • EXPO 1990
  • GRFS 2006
  • Fundamental
  • Price
  • EXPO $90.67
  • GRFS $7.51
  • Analyst Decision
  • EXPO Strong Buy
  • GRFS Strong Sell
  • Analyst Count
  • EXPO 1
  • GRFS 1
  • Target Price
  • EXPO $120.00
  • GRFS N/A
  • AVG Volume (30 Days)
  • EXPO 248.6K
  • GRFS 1.3M
  • Earning Date
  • EXPO 01-30-2025
  • GRFS 01-01-0001
  • Dividend Yield
  • EXPO 1.24%
  • GRFS N/A
  • EPS Growth
  • EXPO 4.07
  • GRFS N/A
  • EPS
  • EXPO 2.06
  • GRFS 0.27
  • Revenue
  • EXPO $508,598,000.00
  • GRFS $7,814,096,584.00
  • Revenue This Year
  • EXPO $5.52
  • GRFS $8.86
  • Revenue Next Year
  • EXPO $5.48
  • GRFS $7.00
  • P/E Ratio
  • EXPO $44.02
  • GRFS $33.24
  • Revenue Growth
  • EXPO 2.56
  • GRFS 7.21
  • 52 Week Low
  • EXPO $68.70
  • GRFS $5.30
  • 52 Week High
  • EXPO $115.75
  • GRFS $12.15
  • Technical
  • Relative Strength Index (RSI)
  • EXPO 29.96
  • GRFS 44.79
  • Support Level
  • EXPO $90.31
  • GRFS $7.41
  • Resistance Level
  • EXPO $94.55
  • GRFS $8.13
  • Average True Range (ATR)
  • EXPO 2.26
  • GRFS 0.31
  • MACD
  • EXPO -0.37
  • GRFS 0.06
  • Stochastic Oscillator
  • EXPO 5.84
  • GRFS 45.13

About EXPO Exponent Inc.

Exponent Inc provides engineering and scientific consulting services on a project-by-project basis. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which accounts for the majority of revenue, provides servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

About GRFS Grifols S.A.

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Share on Social Networks: